



Australian Government

IP Australia

AUSTRALIAN OFFICIAL JOURNAL

OF

PATENTS

Contents

General Information & Notices**Amendments, Section 104**

Applications for Amendment 1085

Applications Accepted

Name Index 1085

Numerical Index 1087

IPC Index 1087

Applications Lapsed, Refused Or Withdrawn**Patents Ceased or Expired** 1084**Assignments before Grant, Section 113** 1085**Assignments Registered** 1088**Corrigenda** 1088**Extensions of Time, Section 223** 1085**Letters Patent Sealed** 1088**Specifications Republished** 1088

General Information

EDITORIAL ENQUIRIES

All enquiries about official notices and general information in the Journal should be directed to IP Australia,
(ABN No 38 113 072 755),
PO Box 200 Woden ACT 2606

Or

Telephone 1300 651 010
(International Callers +61 2 6283 2999)
Fax 02 6283 7999
E-mail assist@ipaustalia.gov.au

CONTACT INFORMATION

Customer Service Network
Telephone 1300 651 010 , Fax: 02 6283 7999
E-mail: assist@ipaustalia.gov.au

Customers can contact the Customer Service Network by telephone or by e-mail. Telephones are staffed between 9am and 5pm each working day.

Customers should contact the Customer Service Network for information about:

- All Patent Matters including PCT and Innovation Patents.
- All Trade Mark Matters.
- All Design Matters.

Professional Standards Board for Patent and Trade Mark Attorneys.

Ph: 02 6283 2345 Fax: 02 6283 1048

ORDERING PATENT DOCUMENTS

When ordering copies of Australian patent specifications, or abstracts and abridgments notified as open to public inspection on or after 26 October 1978, or as accepted on or after 16 November 1978, the documents should be referred to by application numbers only, preceded by letters AU-A or AU-B respectively.

REQUESTS FOR INFORMATION UNDER SECTION 194 (C)

A request for information under Section 194 (C) of the Patents Act 1990 should be made in the approved form and be accompanied by the prescribed fee. The request should be as detailed as possible.

INFORMATION FROM REGISTERS

All requests for information from Register of Patents, Trade Marks or Designs, should be made in writing and accompanied by the prescribed fee. The Registers are located in Canberra and may be examined free of charge.

COUNTRY CODES

For a listing of country codes used by IP Australia please refer to the Official Journals dated 7 November 1996.

ABBREVIATIONS IN JOURNAL

Standard abbreviations are used in the name of companies and firms. Enquiries concerning the precise name should be directed to the Customer Service Network.

FREEDOM OF INFORMATION ACT

What does it do?

- Gives you right to obtain information held by Commonwealth Ministers, Departments and most statutory bodies (these bodies are called agencies under the Act).
- Requires Commonwealth Government agencies to make available to members of the public:
 - Information about agencies, their functions and operations.
 - Information about rules and practices which are used in making decisions which affect you.
- Gives you a legal right to:
 - See non exempt documents held by agencies, and
 - appeal against a decision not to grant access to a document.

What documents can you see?

- The Act gives you a right to see documents lodged on or after 1 December 1977, or earlier if you need them to understand another document you have already.
- Documents include files, reports, computer printouts, maps, plans, photographs, tape recordings, films or videotapes.
- Documents which are available for purchase under the Patents Act 1990, the Trade Marks Act 1995 or Designs Act 2003 are not available under the Freedom of Information Act (Section 12 refers).

How do you apply?

Requests for access to documents must

- Be in writing
- Provide sufficient information so as to enable identification of the documents requested
- Specify an address in Australia where notices can be sent and
- Be accompanied by the application fee (currently \$30.00) or specify an IP Australia account to which the charges will be posted.

Requests for documents should be addressed to IP Australia, PO Box 200 Woden, ACT 2606, or Faxed to 02 6283 7999

DECISIONS OF THE COMMISSIONER OF PATENTS AND REGISTRAR OF TRADE MARKS AND DESIGNS

- All decisions of the Commissioner and Registrars are available free of charge from AUSTLII's website www.austlii.edu.au

Copies of all written Patent and Design decisions are available (except if they would not be available under the provisions of the Freedom of Information legislation, e.g. if they would effectively disclose matter from documents that are not open to public inspection) on request for a cost of \$AU 25. They are also available for inspection in indexed volume series, dating from 1 January 1987, in the Office library, Canberra.

Copies of Trade Mark decisions may be accessed via IP Australia's website www.ipaustralia.gov.au

- Copies of the taped record of Patent and Design hearings are available (with the same exception as above) on request.
- When a written decision is issued the fact of the decision plus a brief head note will be published in the Official Notices section of the next available Patents, Trade Marks or Designs Journal.

HEARINGS BEFORE THE COMMISSIONER OF PATENTS

Hearings before the Commissioner of Patents will usually be conducted at the Patent Office in Canberra and interstate hearing sessions are not provided. However, the Commissioner will conduct hearings outside of Canberra at a convenient time to all parties provided that the parties bear the travel costs of the hearing officer.

The various options for hearings are set out in the document "Options for Hearings" available on IP Australia's website at: www.ipaustralia.gov.au/pdfs/patents/optionsforhearings.PDF

HEARINGS BEFORE THE REGISTRARS OF TRADE MARKS AND DESIGNS

Hearings before the Registrars of Trade Marks and Designs will be set down in Melbourne, Sydney, Adelaide, Perth and Brisbane during the periods indicated below.

Designs and Trade Marks Hearings Sessions 2006

Melbourne	13 – 17 February 5 – 9 June 11 – 15 September
Sydney	13 – 17 March 17 – 21 July 16 – 20 October
Adelaide	14 – 15 August
Perth	17 – 18 August
Brisbane	24 – 25 August

Persons who desire matters to be set down for hearing in Melbourne, Sydney, Adelaide, Perth or Brisbane must give at least one month's notice of their intention to be heard. If such notice is not given, it may be that there would be insufficient time to allow for the execution of official procedures associated with the listing of hearings, and as a result, the matter involved might not be listed.

Subject to the convenience of this Office, hearings will be set down in Canberra at any time suitable to the parties.

LIST OF STATE OFFICES

IP Australia State Offices are located in the Australian Capitals at the addresses given below. Requests for information may be obtained by calling at, phoning or writing to these offices or IP Australia, Canberra.

Australian Capital Territory

Ground Floor
Discovery House
PHILLIP ACT 2606
(PO Box 200, WODEN ACT 2606)
Ph: 1300 651 010
Fax: (02) 6283 7999

New South Wales

Level 1
45 Clarence Street
SYDNEY NSW 2000
Ph: 1300 651 010
Fax: (02) 9249 5807

Victoria

Level 6
OCBC House
565 Bourke Street
MELBOURNE VIC 3000
Ph: 1300 651 010
Fax (03) 9612 9807

Western Australia

2nd Floor
East Point Plaza
233 Adelaide Terrace
PERTH WA 6000
Ph: 1300 651 010
Fax: (08) 9220 8907

Queensland

Level 1
Grant Thornton House
102 Adelaide Street
BRISBANE QLD 4000
Ph: 1300 651 010
Fax: (07) 3007 1107

South Australia

Level 10
Origin Energy House
1 King William Street
ADELAIDE SA 5000
Ph: 1300 651 010
Fax: (08) 8239 4507

Tasmania

4th Floor
AMP Building
27 Elizabeth Street
HOBART TAS 7000
Ph: 1300 651 010
Fax: (03) 6235 6307

GUIDE TO THE USE OF THIS JOURNAL

The Australian Official Journal of Patents (**AOJP**) reports on all the major events and actions which take place during the life cycle of an Australian patent and provides certain details of these actions as they relate to the patent or patent application involved. This guide sets out to teach the reader how to use the journal to access this information.

While there are many possible actions in the life of a patent, the majority of actions reported relate to the following events, which are the main stages in the progression of a patent application to a sealed patent:

(i) FILING –

This is the act of making an application. When the application is first filed certain details are published.

(ii) OPEN-TO-PUBLIC-INSPECTION (OPI) –

Approximately 18 months after first filing of an Australian or a corresponding foreign application, certain application documents, including the complete specification, become available to the public (Open-to-Public-Inspection or “OPI”). Relevant application details are published. In addition, an Abstracts Supplement to the AOJP contains abstracts of the inventive content of the OPI applications.

(iii) ACCEPTANCE -

This is the Commissioner’s acceptance of a patent application. Once the Commissioner has accepted a patent application, certain details of the application are published in the AOJP. In addition, an Abridgments Supplement contains an abridgment (usually the broadest accepted claim and relevant drawing where appropriate) for each accepted application. Notice of opposition may be filed within three months of advertisement of acceptance.

(iv) OPPOSITION –

If an opposition action is commenced against the grant of the patent, the six-figure acceptance number and the name of the opponent are published.

(v) SEALING –

Most accepted applications are not opposed. These proceed to sealing and become granted patents. Of the few that are opposed (less than 1%) most of these, after resolution of the opposition, proceed to sealing and become granted patents. Sealed patents are simply listed in order of their six-figure acceptance number.

In addition to the actions related to these stages, other actions reported include: assignments, lapsing or withdrawal of applications and ceasing or expiry of patents, voluntary amendments, extensions of time for certain actions and registration of licences.

How To Identify Information Using “INID” Numbers

Patents are published in many different languages. As a result, finding the information that you want (eg the filing date) on a patent document or in a journal can be quite difficult. There is an international system operating, however, which codifies this information in an unambiguous way, by assigning a specific number to each piece of information about the history of a patent. These numbers are called the international agreed Numbers for the identification of Data or INID numbers.

These numbers appear on all published patents and abstracts and are used throughout this journal to identify particular items of information. For example, the data on which a document is filed has the INID number (22), while the name of the applicant has the INID number (71). These numbers are always expressed in parentheses and always immediately precede the information to which they relate. For example:

(22) 12.10.91

means that the filing date of the document which contains this reference is 12 October 1991. Learning the INID numbers for the information you want will help you find it quickly and easily.

A complete list of the INID numbers and the items to which they relate is provided at the end of this Guide.

How Australian Patent Documents are Numbered

Patent applications in Australia are assigned numbers at various stages in their processing. Each Australian application which proceeds to acceptance will have at least two (and sometimes more) different numbers during its life. When searching for information and ordering documents it is vital that you understand the numbering systems.

1. **Provisional Applications** are given a number with two characters and four numbers

e.g. **PM1234**

A provisional application number is identified by the INID number (21).

2. **Complete Applications** are given a five-figure application number followed by the last two digits of the year of filing

e.g. **12345/93**

There are prefixes applied to this number which indicate whether the application has been accepted:

A document corresponding to an **unaccepted** application has the prefix, **AU-A**; e.g. AU-A-12345/93.

A document corresponding to an **accepted** application carries the prefix **AU-B**; e.g. AU-B-12345/93.

Users need to be aware that an accepted document may differ from the corresponding unaccepted document. This is because **amendment** may occur between first publication (OPI) and second publication (acceptance).

A five-figure application number is identified by the INID numbers (11) or (21).

3. When a patent application is **accepted** it is given a six-figure document number in addition to the five-figure application number
e.g. 123456

This is the number you must use to keep track of the application in the AOJP from now on. It is identified by the INID number (10).

NOTE: When ordering any patent document from us, whether accepted or not, please quote the five-figure application number preceded by the appropriate prefix.

Arrangement of Information in the Journal

For each of the categories

- (i) Provisional Applications Filed,
- (ii) Complete Applications Filed
- (iii) Applications Open to Public Inspection, and
- (iv) Applications Accepted

The Journal lists the information published in that category in an alphabetical **Name Index** list based on the name of the applicant. These indices are useful if you wish to find information about applications made by a particular applicant.

In addition to the Name Index there is provided, for each of these categories, a **Numerical Index**. This index lists the applications either in order of their five-figure Application Numbers, in the case of complete applications filed and applications OPI, or in order of their six-figure Document Number in the case of accepted applications. It provides, for each number, the name of the applicant. These indices are useful if you wish to track the progress of a particular patent application.

There are also **IPC indices** provided for applications which are OPI and for applications which have been accepted. IPC stands for International Patent Classification. Each IPC symbol is an alpha-numerical representation of a particular area of technology. These indices are in order of IPC symbol, and within each symbol provide either the five-figure application numbers of the applications which are now OPI or the six-figure numbers of the cases now accepted. These indices are useful if you wish to check on patent activity in a particular technology.

Using the Indices

1. To Find Patent Information If You Know the Name of the Applicant.

Use the Name Indices. They will give you the following information identified by their INID number:

<u>ITEM</u>	<u>INID No.</u>	<u>ITEM</u>	<u>INID No.</u>
A) Provisional applications filed – Name Index		B) Complete applications filed – Name Index	
The <u>name</u> of the applicant	(71)	The <u>name</u> of the applicant	(71)
The <u>Provisional application number</u>	(21)	The <u>number</u> assigned to the application	(21)
The <u>date</u> of filing	(22)	The <u>date</u> of filing	(22)
The <u>title</u> of the invention	(54)	<u>Title</u> of the invention	(54)
		<u>Number</u> of priority document(s) if any	(31)
		<u>Date(s)</u> of filing of priority documents	(32)
		<u>Country</u> in which priority document filed	(33)
		PCT application <u>number</u>	(86)
<u>ITEM</u>	<u>INID No.</u>	<u>ITEM</u>	<u>INID No.</u>
C) Applications open to public inspection – Name Index		D) Applications accepted – Name Index	
The <u>name</u> of the applicant	(71)	The <u>name</u> of the applicant	(71)
The <u>number</u> of the document	(11)	The <u>number</u> of the document	(11)
The <u>number</u> assigned to the application	(21)	The <u>number</u> of the accepted document	(10)
The <u>date</u> of filing	(22)	The <u>number</u> assigned to the application	(21)
The <u>title</u>	(54)	The <u>date</u> of filing	(22)
International patent <u>classification symbols</u>	(51)	The <u>title</u>	(54)

Priority document <u>number(s)</u>	(31)	International patent <u>classification symbols</u>	(51)
<u>Date</u> of filing of priority document(s)	(32)	PCT publication <u>number</u>	(87)
<u>Country</u> in which priority document filed	(33)	Priority document <u>number(s)</u>	(31)
Publication <u>date</u> of unexamined document	(43)	<u>Date</u> of filing of priority document(s)	(32)
Inventors <u>names</u> if known	(72)	<u>Country</u> in which priority document filed	(33)
<u>Patent Attorneys</u>	(74)	Publication <u>date</u> of unexamined document	(43)
Related by addition	(61)	Publication <u>date</u> of examined document	(44)
Related by division	(62)	Publication <u>date</u> of granted document	(45)
		Inventors <u>names</u> if known	(72)
		<u>Patent Attorneys</u>	(74)
		Related by addition	(61)
		Related by division	(62)

You will notice at each stage of following an application through that all applications are in alphabetical order of Applicant, not inventor.

2. To Find Information About a Patent Application If You Know Its Number.

Use the appropriate numerical index. This will give you the name of the applicant from the number. You will then need to use the appropriate Name Index as above to find out other information about the Patent Application you are interested in.

The following Numerical Indices are available:

- A) **Provisional** Applications filed.
- B) **Complete** Applications filed.
- C) Applications **Open to Public Inspection**.
- D) Applications **Accepted** (note that this uses six-figure document numbers rather than five-figure application numbers).

3. To Find Information About Patent Documents in the Technical Subject that You are Interested in if You Know the International Patent Classification Symbol for that Technical Subject.

All patent applications are classified according to their technical subject matter using the International Patent Classification (**IPC**). Although the system is very detailed and covers all technologies, knowledge of the IPC symbols of the technical subject that you are interested in will allow you to find patent documents in those technologies quite easily. To identify the IPC symbols for the technical subject that you are interested in, please consult the official IPC web page at <http://www.wipo.int/classifications/ipc/ipc8>. This web page has extra aids to locate the classification symbols such as a catchword index, definitions and illustrations. The IPC symbols may appear in publications in boldface (for "invention information") or regular typeface (for "additional information"). The italic typeface indicates that IP Australia classifies into the advanced level of IPC. The version indicator after each IPC symbol, e.g. (2006.01), indicates the year and the month that the symbol first appeared in IPC.

The indices to use are

- A) Applications **OPI** – IPC Index
- B) Applications **Accepted** – IPC Index.

These indices give you the numbers of the applications which are either OPI or Accepted and are listed in order of their IPC symbols.

Once you have the numbers of the documents that interest you, consult the relevant Number Index (see 2. above) to find the applicant's name, and then the Name Index (see 1. above) to find out the details of that application.

INID NUMBERS in use on Australian Patent Documents

INID is an acronym for 'Internationally agreed Numbers for the Identification of Data'.

(10) Document Identification

- (11) Number of the document
- (12) Plain language designation of the kind of document.
- (19) WIPO country code, or other identification, of the country publishing the document.

(20) Document filing data

- (21) The number(s) assigned to the application(s)
- (22) Date(s) of filing application(s)
- (23) Other date(s) of filing, including exhibition filing date of filing complete specification following provisional specification.
- (24) Date from which industrial property rights may have effect.

(30) Priority date

- (31) Number(s) assigned to priority application(s)
- (32) Date(s) of filing priority application(s)
- (33) Country (countries) in which the priority application(s) was (were) filed.

(40) Date(s) of making available to the public

- (43) Date of publication by printing or similar process of an unexamined document, on which no grant has taken place on or before the said date.
- (44) Date of publication by printing or similar process of an examined document, on which no grant has taken place on or before the said date.
- (45) Date of publication by printing or similar process of a document, on which grant has taken place on or before the said date.

(50) Technical Information

- (51) International Patent Classification.
- (52) Domestic or national classification.
- (54) Title of invention.
- (56) List of prior art documents, if separate from descriptive text.
- (57) Abstract or claim.

(60) Reference(s) to other legally related domestic document(s)

- (60) Related by cognate(s).
- (61) Related by addition(s)
- (62) Related by division(s).

(70) Identification of parties concerned with document

- (70) Name(s) of nominated person
- (71) Name(s) of applicant(s).
- (72) Name(s) of inventor(s) if known to be such.
- (74) Name(s) of attorney(s) or agent(s).
- (75) Name(s) of inventor(s) who is (are) also applicant(s)

(80) Identification of data related to International Conventions other than the Paris Convention

- (86) PCT Application Number.
- (87) PCT Publication Number.

NOTE:

(1) Australian patent documents published on or after 26 October 1978 should be referred to by the application number preceded by the AU-A or AU-B.

AU-A = Pre-examination

AU-B = Post-examination

(2) The classification used is the International Patent Classification and is identified by the INID code (51). Further editions of the classification are identified as (51)², (51)³, (51)⁴ and (51)⁵.

(3) INID code 74 provides for the name of patent attorney, or firm of attorneys, prosecuting an application.

(4) No provision is made for addresses for service. Addresses for service of applicants not represented by an independent attorney or firm are viewable at www.ipaustralia.gov.au and on sale at the IP Australia State Offices.

OFFICIAL NOTICES

IP Australia State Office Relocation Notice

IP Australia is pleased to announce that the NSW and SA/NT State offices of IP Australia will be moving to new premises.

Effective dates:

- NSW Monday November 27, 2006
- SA/NT Monday December 4, 2006.

Location:

- NSW

The new office is located approximately 5km from Sydney's central business district, 8km from Sydney Airport and within 200m of Sydney's rail network.

The new address will be:

**Level 1, Bay 8
 Locomotive Workshop
 Australian Technology Park
 EVELEIGH NSW 1430**




Location:

- SA/NT

The new office is located approximately 12 km north from Adelaide's central business district.

The new address will be:

**Innovation House East Wing
Mawson Lakes Boulevard
MAWSON LAKES SA 5095**



The phone number, facsimile and e-mail addresses details for both offices remain unchanged:

Phone: 1300 651 010
Fax: (02) 6283 7999
Email address: assist@ipaaustralia.gov.au

Queries: Micahel Debenham
Customer Operations Group
+61 2 6283 2083

Contact: IP Australia
Phone: 1300 651 010 or +61 2 6283 2999
Fax: +61 2 6283 7999
E-mail: assist@ipaaustralia.gov.au
Web: www.ipaaustralia.gov.au

OFFICIAL NOTICES

2006 Christmas Holiday Close Down

IP Australia's Certified Agreement provides for a Christmas close down period between Christmas Day and New Year's Day. This means that the majority of IP Australia's staff will be on leave for the period 25 December 2006 until 2 January 2007 inclusive. However, Thursday 28 and Friday 29 December 2006 are not public holidays for the purposes of the Patents, Trade Marks, Designs or Plant Breeder's Rights Acts. This means that all deadlines that fall due on the 28 and 29 December 2006 will still need to be met by customers.

In order to provide essential services to our customers on the days of 28 and 29 December 2006, all State Offices with the exception of Hobart, will remain open on these two days to receive applications, payments and other documents and to provide searching facilities. Our Customer Service Number, 1300 651 010, will also be available to answer enquiries.

Tasmanian customers requiring essential services during the close down are asked to use the national customer service number 1300 651 010.

Customers calling from outside Australia should call +61 2 6283 2999.

It should also be noted that no administrative or examination work will be undertaken during the close down period 25 December 2006 - 2 January 2007

To assist us to deal with urgent matters, customers are requested to send all non-urgent work outside of the Christmas close down period.

Where critical deadlines fall due on a day during the Christmas close down (25 December 2006 to 2 January 2006 inclusive), customers are advised to undertake necessary action prior to the Christmas close down. Some examples of these critical deadlines include:

- the 21-month finalisation date for patent examination;
- making a response to place a design application in order for registration;
- urgent requirement for a certified copy;
- the end of the 6 month period in which a person may file an application for registration of a trade mark in Australia and claim a right of priority from an application they filed overseas in a convention country for the same trade mark;
- final date for acceptance of a trade mark;
- the end of the 15 month period in which a request for deferment of acceptance of a trade mark application may be made; and
- lodgement of Part 1 applications for Plant Breeder's Rights where the period for prior sale is likely to expire during the closedown period.

If you have any specific enquiries regarding the close down period please contact the Customer Service Numbers provided below for referral to a designated contact officer, depending on the nature of your enquiry.

Customers are also reminded of IP Australia's contact details, as listed below. All business correspondence during the close down period should be via these means. It is particularly important to use these contact details over the Christmas close down period, as other numbers may not be staffed.

Queries: Renata Rose
Customer Services Network
+61 2 6283 2193

Contact: IP Australia

Phone: 1300 651 010

Fax: +61 2 6283 7999

E-mail: assist@ipaustralia.gov.au

Web: www.ipaustralia.gov.au

Proceedings under the Patents Act 1990

Appls Lapsed:W/drawn, Pat. Ceased:Exp/d cont'd

Applications Lapsed, Refused Or Withdrawn
Patents Ceased or Expired

Reference to the application numbers must include the year of the application of the patent, which is shown preceding the numbers.

The codes next to each number have the following meanings:

Code	Meaning
1	Application Lapsed Section 142(2)(a) \S 47(C)\
2	Application Lapsed Section 142(2)(b)
3	Application Lapsed Section 142(2)(c) \S 52B(3)\
4	Application Lapsed Section 142(2)(d) \S 47D(1)\
5	Application Lapsed Section 142(2)(e) \S 53\
6	Application Lapsed Section 142(2)(f)/Reg 8.3(3)
7	Application Lapsed Reg. 3.2(5)(a) \R 7B(3)\
8	Application Lapsed Reg. 3.4(6)
9	Application Lapsed Section 142(3)
10	Application Lapsed Section 142(4)(b)
11	Application Lapsed Section 148(1)(c)
12	Application Withdrawn Section 141(1)/Reg 8.3(2) \S 37\
13	Application Withdrawn Section 141(2)/Reg 8.3(2)
14	Patent Ceased Section 143(a), or Expired
15	Patent Ceased Section 143(b)
16	Application refused
17	Application Lapsed Regulation 22.2
A	Applications on which examination has not been requested or directed
B	Applications on which a direction to request examination has been given
C	Applications on which examination has been requested or on which an examination report has been issued
D	Applications which have been accepted or advertised accepted, (including applications which have also been advertised 'Not Sealed')
N	Applications Not Open to Public Inspection

668494 (14)	668710 (14)	668712 (14)
669046 (14)	669069 (14)	670857 (14)
672475 (14)	672666 (14)	673256 (14)
673596 (14)	673732 (14)	673914 (14)
674300 (14)	674451 (14)	675932 (14)
677307 (14)	677625 (14)	677648 (14)
678319 (14)	678320 (14)	678679 (14)
679028 (14)	679351 (14)	679363 (14)
680101 (14)	680657 (14)	681634 (14)
681953 (14)	684891 (14)	684930 (14)
685091 (14)	688022 (14)	691404 (14)
691486 (14)	694753 (14)	695139 (14)
695298 (14)	695980 (14)	696846 (14)
697363 (14)	699092 (14)	699706 (14)
701031 (14)	702885 (14)	705958 (14)
706011 (14)	707071 (14)	707993 (14)
709823 (14)	709929 (14)	710283 (14)
710615 (14)	712171 (14)	712525 (14)
712948 (14)	713122 (14)	713450 (14)
713811 (14)	716568 (14)	716576 (14)
716579 (14)	718190 (14)	720179 (14)
721916 (14)	722424 (14)	722650 (14)
724428 (14)	725091 (14)	725623 (14)
726024 (14)	726372 (14)	726390 (14)
726795 (14)	729052 (14)	729744 (14)
729902 (14)	730681 (14)	731905 (14)
732009 (14)	732113 (14)	733878 (14)
734286 (14)	735324 (14)	736335 (14)
736516 (14)	736648 (14)	737974 (14)
737979 (14)	738461 (14)	739018 (14)
740079 (14)	740224 (14)	740387 (14)
740454 (14)	740949 (14)	741391 (14)
741411 (14)	741834 (14)	743489 (14)
744036 (14)	746715 (14)	747442 (14)
747812 (14)	748080 (14)	748299 (14)
748333 (14)	749579 (14)	749762 (14)
750149 (14)	750788 (14)	751810 (14)
752035 (14)	753806 (14)	754104 (14)
755503 (14)	755652 (14)	756651 (14)
757599 (14)	758191 (14)	759156 (14)
760804 (14)	760926 (14)	760977 (14)
761107 (14)	761601 (14)	762095 (14)
762242 (14)	762592 (14)	762753 (14)
763288 (14)	763472 (14)	763568 (14)
764151 (14)	767815 (14)	768524 (14)
540433 (14)	562277 (14)	568791 (14)
570838 (14)	572019 (14)	574270 (14)
574620 (14)	576952 (14)	577452 (14)
579921 (14)	580474 (14)	581064 (14)
581065 (14)	581974 (14)	582081 (14)
583204 (14)	583360 (14)	583599 (14)
585140 (14)	587739 (14)	588289 (14)
589165 (14)	590545 (14)	590836 (14)
592792 (14)	592982 (14)	593495 (14)
594327 (14)	594618 (14)	595507 (14)
596402 (14)	597573 (14)	597802 (14)
598458 (14)	599314 (14)	599534 (14)
599901 (14)	604536 (14)	605974 (14)
607848 (14)	608300 (14)	608956 (14)
609954 (14)	614225 (14)	615135 (14)
615767 (14)	616961 (14)	617162 (14)
617638 (14)	622303 (14)	622305 (14)
625535 (14)	626180 (14)	626648 (14)
629545 (14)	633201 (14)	633668 (14)
634004 (14)	635370 (14)	643201 (14)
650728 (14)	650955 (14)	651181 (14)
652143 (14)	652510 (14)	657742 (14)
658720 (14)	659629 (14)	663506 (14)

Appls Lapsed:W/drawn, Pat. Ceased:Exp/d cont'd

768621 (14)	768720 (14)	769453 (14)
769826 (14)	771615 (14)	772215 (14)
772837 (14)	773223 (14)	774871 (14)
775335 (14)	775358 (14)	775372 (14)
776564 (14)	778375 (14)	779143 (14)
780403 (14)	782093 (14)	782743 (14)
782876 (14)	783170 (14)	783781 (4D)
44496 (4C)		
2001		
26478 (4C)	27980 (4C)	43680 (4C)
45654 (4C)	47556 (4C)	50881 (4C)
52189 (4C)	60128 (4C)	

Assignments before Grant, Section 113

780541 Beverly Glen Medical Systems, Inc. The application has been assigned to **Prairie Life L.L.C.**

Extensions of Time, Section 223

Applications Allowed - Section 223(2)

704777 **Swinburne University of Technology** The time in which to pay a renewal fee has been extended to 26 Aug 2006 . Address for service in Australia - Jill Evans c/- Rinker Australia Pty Ltd L8, Tower B, 799 Pacific Hwy Chatswood NSW 2067

750374 **SDC Coatings, Inc.** The time in which to pay a renewal fee has been extended to 16 May 2006 . Address for service in Australia - WRAYMARK SERVICES PO Box Z5466 St Georges Terrace PERTH WA 6831

771095 **Wilkinsons Blacksmiths Pty Ltd.** The time in which to pay a renewal fee has been extended to 13 Jun 2006 . Address for service in Australia - John Raymond Wilkinson Wilkinsons Blacksmiths Pty Ltd 1 Gill Street Atherton QLD 4883

Extensions of Time, Section 223 -cont'd

775664 **Hoppy, Societe a Responsabilite Limitee** The time in which to pay a renewal fee has been extended to 14 Apr 2006 . Address for service in Australia - SPRUSON & FERGUSON GPO Box 3898 SYDNEY NSW 2001

784036 **Graphic Packaging International, Inc.** The time in which to provide search results under S45(3) has been extended to 21 Jul 2006 . Address for service in Australia - PHILLIPS ORMONDE & FITZPATRICK 367 Collins Street MELBOURNE VIC 3000

Amendments, Section 104

Applications for Amendment

A person interested in opposing the allowance of the amendment may, at any time within three months from the date of this journal, give notice at the Patent Office using the approved form accompanied by the prescribed fee.

754918 Mixtures for weed control in glyphosate tolerant soybeans **Monsanto Technology LLC** The nature of the proposed amendment is as shown in the statement(s) filed 21 Oct 2005, 2 Mar 2006 and 15 May 2006. . Address for service in Australia - E F Wellington & Co 312 St Kilda Road MELBOURNE VIC 3006

773176 Method of producing a diffractive structure in security documents **Securrency Pty Ltd.** The nature of the proposed amendment is as shown in the statement(s) filed 2 Oct 2006. . Address for service in Australia - WATERMARK PATENT & TRADEMARK ATTORNEYS Locked Bag 5 HAWTHORN VIC 3122

783278 Genomic profiling: a rapid method for testing a complex biological sample for the presence of many types of organisms **Genomic Profiling Systems, Inc.** The nature of the proposed amendment is as shown in the statement(s) filed 30 Aug 2006. . Address for service in Australia - Griffith Hack GPO Box 1285K MELBOURNE VIC 3001

Applications Accepted

Name Index

. The Nominated Person(s) (INID 70) are listed only if they differ from the Applicant(s) (INID 71). Otherwise only the Applicant(s) are listed.

(71) Baker Hughes Inc.	E21B 43/14 (2006.01)
(11) AU-B-16809/02 (10) 785197	E21B 43/267 (2006.01)
(21) 16809/02 (22) 21.02.02	(31) 09/793244 (32) 26.02.01 (33) US
(54) LOCK RING FOR PIPE SLIP PICK-UP RING	(43) 29.08.02
(51) Int. Cl.	(44) 02.11.06
E21B 23/01 (2006.01)	(72) Womble, A.W.
(31) 09/797215 (32) 01.03.01 (33) US	(74) Freehills Patent & Trade Mark Attorneys
(43) 05.09.02	(71) Baker Hughes Inc.
(44) 02.11.06	(11) AU-B-85524/01 (10) 785206
(72) Doane, J.C.	(21) 85524/01 (22) 30.10.01
(74) Freehills Patent & Trade Mark Attorneys	(54) BACTERIA-BASED AND ENZYME-BASED MECHANISMS AND PRODUCTS FOR VISCOSITY REDUCTION BREAKING OF VISCOELASTIC FLUIDS
(71) Baker Hughes Inc.	(51) Int. Cl.
(11) AU-B-16789/02 (10) 785201	C09K 8/60 (2006.01)
(21) 16789/02 (22) 20.02.02	C09K 8/62 (2006.01)
(54) SINGLE TRIP, MULTIPLE ISOLATION, WELL FRACTURING SYSTEM	(31) 60/244804 (32) 31.10.00 (33) US
(51) Int. Cl.	(43) 23.05.02
E21B 43/04 (2006.01)	

(44) 02.11.06
(72) Crews, J.B.
(74) Freehills Patent & Trade Mark Attorneys
(71) Cochlear Ltd.
(11) AU-B-21298/02 (10) 785210
(21) 21298/02 (22) 07.03.02
(54) TOTALLY IMPLANTABLE HEARING SYSTEM
(51) Int. Cl.
H04R 25/00 (2006.01)
A61N 1/36 (2006.01)
(31) 10114838 (32) 26.03.01 (33) DE
(43) 03.10.02
(44) 02.11.06
(72) Baumann, J.W.; Leysieffer, H.
(74) F B Rice & Co
(71) Cooper, M.R.
(11) AU-B-79368/01 (10) 785195

Applications Accepted - Name Index cont'd

(21) 79368/01	(22) 11.10.01	0026891	01.11.00	GB	(87) WO01/36487		
(54) SERVICE MANAGEMENT SYSTEM					(31) 60/165555	(32) 15.11.99	(33) US
(51) Int. Cl.		0028097	20.11.00	GB	60/167076	23.11.99	US
<i>G06Q 10/00</i> (2006.01)							
<i>G06Q 30/00</i> (2006.01)		0028693	27.11.00	GB	60/179003	28.01.00	US
(31) PR0877	(32) 18.10.00	(33) AU					
(43) 02.05.02		0029148	30.11.00	GB	60/180775	07.02.00	US
(44) 02.11.06							
(72) Cooper, M.R.		0031164	21.12.00	GB	60/196824	11.04.00	US
(74) Fisher Adams Kelly							
		0031680	27.12.00	GB	60/197205	13.04.00	US
(71) D. and V. O'Neill Pty Ltd.		(43) 21.01.02			(43) 30.05.01		
(11) AU-B-24804/01	(10) 785200	(44) 02.11.06			(44) 02.11.06		
(21) 24804/01	(22) 01.03.01	(72) Irvine, N.S.			(72) Schmitz, J.; Dzionek, A.; Buck, D.W.		
(54) DOOR LOCK		(74) SPRUSON & FERGUSON			(74) SPRUSON & FERGUSON		
(51) Int. Cl.							
<i>E05C 9/06</i> (2006.01)		(71) Konami Corp.			(71) Oracle International Corp.		
<i>E05B 55/14</i> (2006.01)		(11) AU-B-27707/02	(10) 785194		(11) AU-B-20667/01	(10) 785202	
<i>E05B 59/00</i> (2006.01)		(21) 27707/02	(22) 27.03.02		(21) 20667/01	(22) 08.12.00	
<i>E05C 9/16</i> (2006.01)		(54) GAMING MACHINE, GAMING INHIBITION			(54) EDROPSHIP: METHODS AND SYSTEMS		
(43) 05.09.02		METHOD AND PROGRAM FOR			FOR ANONYMOUS ECOMMERCE		
(44) 02.11.06		EXECUTING THE METHOD			SHIPMENT		
(61) 733379		(51) Int. Cl.			(51) Int. Cl.		
(72) O'Neill, D.		<i>A63F 13/00</i> (2006.01)			<i>G06F 17/00</i> (2006.01)		
(74) F B Rice & Co		<i>G07F 17/32</i> (2006.01)			<i>G06Q 10/00</i> (2006.01)		
		(31) 01-089572	(32) 27.03.01	(33) JP	<i>G06Q 20/00</i> (2006.01)		
Dapprich, J. see Trustees of Princeton		(43) 03.10.02			<i>G06Q 30/00</i> (2006.01)		
University		(44) 02.11.06			(87) WO01/53971		
(11) AU-B-20867/01		(72) Kazaoka, K.; Aida, E.			(31) 09/490783	(32) 24.01.00	(33) US
		(74) Griffith Hack			(43) 31.07.01		
					(44) 02.11.06		
(71) DePuy Products Inc		(71) Kyle, P.D.			(72) Johnson, R.C.		
(11) AU-B-50642/02	(10) 785208	(11) AU-B-48859/00	(10) 785205		(74) Davies Collison Cave		
(21) 50642/02	(22) 26.06.02	(21) 48859/00	(22) 27.07.00				
(54) JOINT PROSTHESIS MOLDING METHOD		(54) IMPROVEMENTS IN BIRD CONTROL					
AND DIE FOR PERFORMING THE SAME		APPARATUS					
(51) Int. Cl.		(51) Int. Cl.			(71) Trustees of Princeton University; Dapprich, J.		
<i>B29C 70/72</i> (2006.01)		<i>A01M 29/02</i> (2006.01)			(11) AU-B-20867/01	(10) 785211	
(31) 60/302097	(32) 30.06.01	(43) 31.01.02			(21) 20867/01	(22) 11.12.00	
10/154732	24.05.02	(44) 02.11.06			(54) METHOD FOR SELECTIVELY ISOLATING A		
		(72) Kyle, P.D.			NUCLEIC ACID		
(43) 02.01.03		(74) Don Hopkins & Associates			(51) Int. Cl.		
(44) 02.11.06					<i>C12Q 1/68</i> (2006.01)		
(72) Gundlapalli, R.R.; Heldreth, M.; Burnstein, A.					(87) WO01/42510		
(74) Freehills Patent & Trade Mark Attorneys					(31) 60/170140	(32) 10.12.99	(33) US
					NOT GIVEN	08.12.00	US
(71) GE Capital Commercial Finance, Inc		(71) Lindsay Manufacturing Co.			(43) 18.06.01		
(11) AU-B-22979/02	(10) 785207	(11) AU-B-34294/02	(10) 785204		(44) 02.11.06		
(21) 22979/02	(22) 11.07.01	(21) 34294/02	(22) 12.04.02		(72) Dapprich, J.; Cleary, M.A.		
(54) MULTIVARIATE RESPONSES USING		(54) MOBILE IRRIGATION MACHINE WITH			(74) Cullen & Co		
CLASSIFICATION AND REGRESSION		UNDERGROUND WATER APPLICATION					
TREES SYSTEMS AND METHODS		(51) Int. Cl.			(71) Warner, B.N.		
(51) Int. Cl.		<i>A01G 25/09</i> (2006.01)			(11) AU-B-22980/02	(10) 785196	
<i>G06F 17/18</i> (2006.01)		(31) 09/848665	(32) 03.05.01	(33) US	(21) 22980/02	(22) 06.03.02	
<i>G06Q 40/00</i> (2006.01)		(43) 07.11.02			(54) SHOWER BASE		
(87) WO02/11017		(44) 02.11.06			(51) Int. Cl.		
(31) 09/619278	(32) 19.07.00	(72) Parod, R.W.; Meis, C.H.			<i>A47K 3/40</i> (2006.01)		
		(74) Collison & Co			<i>A47K 3/28</i> (2006.01)		
(43) 13.02.02					<i>A47K 3/30</i> (2006.01)		
(44) 02.11.06					(31) 510350	(32) 06.03.01	(33) NZ
(72) Keyes, T.K.		(71) Miltenyi Biotec GmbH			(43) 12.09.02		
(74) Davies Collison Cave		(11) AU-B-17233/01	(10) 785198		(44) 02.11.06		
		(21) 17233/01	(22) 15.11.00		(72) Warner, B.N.		
(71) Irvine, N.S.		(54) ANTIGEN-BINDING FRAGMENTS			(74) SCHUCH & COMPANY		
(11) AU-B-56467/01	(10) 785203	SPECIFIC FOR DENDRITIC CELLS,					
(21) 56467/01	(22) 03.05.01	COMPOSITIONS AND METHODS OF USE			(71) Watson Pharmaceuticals, Inc.		
(54) ZEROCLICK		THEREOF ANTIGENS RECOGNISED			(11) AU-B-65235/01	(10) 785199	
(51) Int. Cl.		THEREBY AND CELLS OBTAINED			(21) 65235/01	(22) 31.05.01	
<i>G06F 3/033</i> (2006.01)		THEREBY			(54) TRANSDERMAL DELIVERY OF		
(87) WO02/05081		(51) Int. Cl.			LASOFOXIFENE		
(31) 0011321	(32) 11.05.00	<i>C07K 14/705</i> (2006.01)			(51) Int. Cl.		
0011370	12.05.00	<i>A61K 35/12</i> (2006.01)			<i>A61K 9/70</i> (2006.01)		
		<i>A61K 47/48</i> (2006.01)			<i>A61K 31/40</i> (2006.01)		
0011441	12.05.00	<i>A61K 51/10</i> (2006.01)			(87) WO01/91724		
		<i>C07K 16/28</i> (2006.01)			(31) 60/208789	(32) 01.06.00	(33) US
0012582	24.05.00	<i>C12N 5/06</i> (2006.01)					
		<i>G01N 33/50</i> (2006.01)					

Applications Accepted - Name Index cont'd

(43) 11.12.01	(21) 29289/02	(22) 28.03.02	(31) 09/826461	(32) 04.04.01	(33) US
(44) 02.11.06	(54) SINGLE PASS RADIUS MOLDING SYSTEM		(43) 10.10.02		
(72) Fikstad, D.; Quan, D.	(51) Int. Cl.		(44) 02.11.06		
(74) F B Rice & Co	B27C 5/06 (2006.01)		(72) White, R.N.		
	B23Q 5/58 (2006.01)		(74) SPRUSON & FERGUSON		
(71) White, R.N.	B27C 9/04 (2006.01)				
(11) AU-B-29289/02	B27M 3/08 (2006.01)				
(10) 785209					

Numerical Index

785194 Konami Corp.	785203 Irvine, N.S.
785195 Cooper, M.R.	785204 Lindsay Manufacturing Co.
785196 Warner, B.N.	785205 Kyle, P.D.
785197 Baker Hughes Inc.	785206 Baker Hughes Inc.
785198 Miltenyi Biotec GmbH	785207 GE Capital Commercial Finance, Inc
785199 Watson Pharmaceuticals, Inc.	785208 DePuy Products Inc
785200 D. and V. O'Neill Pty Ltd.	785209 White, R.N.
785201 Baker Hughes Inc.	785210 Cochlear Ltd.
785202 Oracle International Corp.	785211 Trustees of Princeton University Dapprich, J.

IPC Index

<u>A01G 25/-</u>	<u>A61K 47/-</u>	<u>B27C 9/-</u>	<u>C12N 5/-</u>	<u>E21B 43/-</u>	<u>G06Q 20/-</u>
785204	785198	785209	785198	785201	785202
<u>A01M 29/-</u>	<u>A61K 51/-</u>	<u>B27M 3/-</u>	<u>C12Q 1/-</u>	<u>G01N 33/-</u>	<u>G06Q 30/-</u>
785205	785198	785209	785211	785198	785195 785202
<u>A47K 3/-</u>	<u>A61N 1/-</u>	<u>B29C 70/-</u>	<u>E05B 55/-</u>	<u>G06F 3/-</u>	<u>G06Q 40/-</u>
785196	785210	785208	785200	785203	785207
<u>A61K 9/-</u>	<u>A63F 13/-</u>	<u>C07K 14/-</u>	<u>E05B 59/-</u>	<u>G06F 17/-</u>	<u>G07F 17/-</u>
785199	785194	785198	785200	785202 785207	785194
<u>A61K 31/-</u>	<u>B23Q 5/-</u>	<u>C07K 16/-</u>	<u>E05C 9/-</u>	<u>G06Q 10/-</u>	<u>H04R 25/-</u>
785199	785209	785198	785200	785195 785202	785210
<u>A61K 35/-</u>	<u>B27C 5/-</u>	<u>C09K 8/-</u>	<u>E21B 23/-</u>		
785198	785209	785206	785197		

Letters Patent Sealed

Standard Patents

780541	782917	784262	784811	784832	784833
784834	784835	784838	784839	784840	784841
784842	784843	784844	784846	784847	784848
784849	784851	784852	784853	784854	784855
784856	784857	784858	784860	784862	784863

Assignments Registered

600404 Taiho Pharmaceutical Company, Limited; Otsuka Kagaku Kabushiki Kaisha The patent has been assigned to **Taiho Pharmaceutical Company, Limited; Otsuka Chemical Co., Ltd**

615884 Taiho Pharmaceutical Company Ltd.; Otsuka Kagaku Kabushiki Kaisha The patent has been assigned to **Taiho Pharmaceutical Company Ltd.; Otsuka Chemical Co., Ltd**

626709 Australian Nuclear Science and Technology Organisation The patent has been assigned to **Steffen, Robertson and Kirsten Australasia Pty Limited**

660688 Jan Gerben Frans Worst The patent has been assigned to **Jan Worst Research Group B.V.**

662105 Novo Nordisk A/S The patent has been assigned to **Eli Lilly and Company**

671792 Rota-Tech Dairy Sheds International Limited The patent has been assigned to **Delaval, Inc.**

674637 Rota-Tech Dairy Sheds International Limited The patent has been assigned to **Delaval, Inc.**

691005 Pfizer Research and Development Company, N.V./S.A. The patent has been assigned to **Pfizer Ireland Pharmaceuticals**

694415 Novo Nordisk A/S The patent has been assigned to **Eli Lilly and Company**

701292 Novo Nordisk A/S The patent has been assigned to **Eli Lilly and Company**

711938 Dreyer's Grand Ice Cream, Inc. The patent has been assigned to **Nestec S.A.**

724907 Phoenix Pharmacologics, Inc. The patent has been assigned to **Enzon Pharmaceuticals, Inc.**

741728 Transgene S.A.; Centre National De La Recherche Scientifique The patent has been assigned to **Transgene S.A.**

743085 University Technology Corporation The patent has been assigned to **The Regents of the University of Colorado**

744955 Rota-Tech Dairy Sheds International Limited The patent has been assigned to **Delaval, Inc.**

747137 University of Utah Research Foundation; Pharmadigm, Inc. The patent has been assigned to **University of Utah Research Foundation**

765567 Aluminium Extrusion and Distribution Pty Limited The patent has been assigned to **Chameleon All Seasons Enclosures**

Assignments Registered - cont'd

Pty Limited

767405 Bayer Cropscience AG The patent has been assigned to **Arysta LifeScience North America**

777819 Siemens Ltd.; Telstra R & D Management Pty Ltd The patent has been assigned to **Siemens Ltd.; Telstra Corporation Limited**

784276 Biotechvisions Limited; Ovita Limited The patent has been assigned to **Biotechvisions Limited; AgResearch Limited**

Corrigenda

In Vol 20, No 34, Page(s) 1037 under the heading **Applications Accepted - Name Index** In the name of Genentech, Inc., Serial No. 785055, INID (22), amend the date to read 11.01.01.

In Vol 20, No 38, Page(s) 1063 under the heading **Patents Ceased or Expired/Applications Lapsed Withdrawn or Refused** Please delete all reference to Patent No. 782070, 782071, 782076, and 782136 in the name of Frama AG.

Specifications Republished

The following specifications contained errors when advertised OPI or Accepted. They have been reissued on the AU-A or AU-B CD-ROM of this Journal date.

784443 **Scripps Research Institute, The and Janssen Pharmaceutica N.V.**

784559 **BOC Group, Inc, The**


784856 **Johnson & Johnson Consumer Companies, Inc.**

785055 **Genentech, Inc.**

Notice of Intention to Amend pursuant to Order 58 Rule 10(1) of the Federal Court Rules

Australian Patent 741818 in the name of Merck and Co., Inc.

AUSTRALIA
Patents Act 1990



NOTICE
OF
APPLICATION TO AMEND LETTERS PATENT
PURSUANT TO SECTION 105

MERCK & CO., INC.

of 126 East Lincoln Avenue
Rahway, NJ 07065-0907

UNITED STATES OF AMERICA

hereby gives notice that it intends to apply under sub-section 105(1) of the Patents Act 1990 for an Order directing the amendment of the Australian Letters Patent No. 741818 for an invention entitled "Method for Inhibiting Bone Resorption" in accordance with the Advertisement lodged herewith.

The Applicant's address for service is C/ CROPPER PARKHILL, Solicitors of Level 20, 9 Castlereagh Street, Sydney, New South Wales 2000.

DATED: 6 October 2006


CROPPER PARKHILL
Solicitor for the Applicants

TO: The Commissioner of Patents
Australian Industrial Property Organisation
PO Box 200
WODEN ACT 2606

SECTION 105 PATENTS ACT

Advertisement pursuant to Order 58 r10(1) of the Federal Court Rules.

IDENTITY OF PROCEEDINGS

Court: Full Federal Court of Australia
New South Wales District Registry
General Division
No. NSD1563 of 2004

Parties: Merck & Co., Inc.
(Applicant)

Arrow Pharmaceuticals Limited (ACN 088 417 403)
(Respondent)

PARTICULARS OF PROPOSED AMENDMENT

Merck & Co., Inc., the registered proprietor of Australian Letters Patent No. 741818 (the "Patent"), will seek an Order under Section 105(1) of the Patents Act 1990 directing the amendment of the Patent as follows:

1. Page 4: Delete text "US Patent... multiple dosages" from lines 16 to 29 as shown in Annexure 1.
2. Page 13: Delete lines 19 to 23 as shown in Annexure 1.
3. Claims Pages Schedule A: Renumber as pages 31 and 32 as shown in Annexure 2.
4. Claims Pages: Correct spelling error "biphosphonate" in claims 5, 6, 7, 8, 9 and 10 to read "bisphosphonate" as shown in Annexure 2.

APPLICANT'S ADDRESS FOR SERVICE

CROPPER PARKHILL
Solicitors
Level 20, 9 Castlereagh Street
SYDNEY NSW 2000
Tel: (02) 9232 5000
Fax: (02) 9232 2467

Attention: John Simpson

OPPOSITION

Any person or corporation intending to oppose the application not being a party to the proceedings must not later than 28 days after the publication of this advertisement, give written notice of that intention to each of the Commissioner of Patents and Merck & Co., Inc. at the above address for service.

IP Australia
09 OCT 2006
P&S

ANNEXURE 1

developed in an attempt to minimize the decline in bone mineralization while still providing a therapeutic anti-resorptive effect. Generally, cyclic regimens are characterized as being intermittent, as opposed to continuous treatment regimens, and have both treatment periods during which the bisphosphonate is administered and nontreatment periods to permit the systemic level of the bisphosphonate to return to baseline. However, the cyclic regimens, relative to continuous dosing, appear to result in a decreased therapeutic antiresorptive efficacy. Data on risedronate suggests that cyclic dosing is actually less effective than continuous daily dosing for maximizing antiresorptive bone effects. See L. Mortensen, et al., *Prevention Of Early Postmenopausal Bone Loss By Risedronate*, *Journal of Bone and Mineral Research*, vol. 10, supp. 1, p. s140 (1995), which is incorporated by reference herein in its entirety. Furthermore, these cyclic regimens do not eliminate or minimize adverse gastrointestinal effects, because such regimens typically utilize periods of multiple daily dosing. Also, the cyclic regimens are cumbersome to administer and have the disadvantage of low patient compliance, and consequently compromised therapeutic efficacy. ~~U.S. Patent No. 5,366,965, to Strein, issued November 22, 1994, which is incorporated by reference herein in its entirety, attempts to address the problem of adverse gastrointestinal effects by administering a polyphosphonate compound, either orally, subcutaneously, or intravenously, according to an intermittent dosing schedule having both a bone resorption inhibition period and a no-treatment rest period. However, the regimen has the disadvantage of not being continuous and regular, and requires nontreatment periods ranging from 20 to 120 days. PCT Application No. WO 95/30421, to Goodship et al, published November 16, 1995, which is incorporated by reference herein in its entirety, discloses methods for preventing prosthetic loosening and migration using various bisphosphonate compounds. Administration of a once weekly partial dose of the bisphosphonate is disclosed. However, the reference specifically fails to address the issue of adverse gastrointestinal effects or to disclose administration of larger or multiple dosages.~~

It is seen from current teachings that both daily and cyclic treatment regimens have shortcomings, and that there is a need for development of a dosing regimen to overcome these shortcomings.

In the present invention, it is found that the adverse gastrointestinal effects that can be associated with daily or cyclic dosing regimens can be minimized by administering the bisphosphonate at a relatively high unit dosage according to a

production has been greatly diminished. However, osteoporosis can also be steroid- induced and has been observed in males due to age. Osteoporosis can be induced by disease, e.g. rheumatoid arthritis, it can be induced by secondary causes, e.g., glucocorticoid therapy, or it can come about with no identifiable cause, i.e. idiopathic

osteoporosis. In the present invention, preferred methods include the treatment or prevention of abnormal bone resorption in osteoporotic humans.

Localized bone loss has been associated with periodontal disease, with bone fractures, and with periprosthetic osteolysis (in other words where bone resorption has occurred in proximity to a prosthetic implant).


Generalized or localized bone loss can occur from disuse, which is often a problem for those confined to a bed or a wheelchair, or for those who have an immobilized limb set in a cast or in traction.

The methods and compositions of the present invention are useful for treating and or preventing the following conditions or disease states: osteoporosis, which can include post-menopausal osteoporosis, steroid-induced osteoporosis, male osteoporosis, disease-induced osteoporosis, idiopathic osteoporosis; Paget's disease; abnormally increased bone turnover; periodontal disease; localized bone loss associated with periprosthetic osteolysis; and bone fractures.

~~_____The methods of the present invention are intended to specifically exclude methods for the treatment and/or prevention of prosthesis loosening and prosthesis migration in mammals as described in PCT application WO 95/30421, to Goodship et al, published November 16, 1995, which is incorporated by reference herein in its entirety.~~

Bisphosphonates

The methods and compositions of the present invention comprise a bisphosphonate. The bisphosphonates of the: present invention correspond to the chemical formula



SCHEDULE A

The claims defining the invention are as follows:

1. A method of preventing osteoporosis in a human, comprising orally administering to said human a pharmaceutically effective amount comprising about 35 mg of alendronate monosodium trihydrate on an alendronic acid active basis as a unit dosage according to a continuous schedule having a dosage interval which is once weekly.
2. A method of treating osteoporosis in a human, comprising orally administering to said human a pharmaceutically effective amount comprising about 70mg of alendronate monosodium trihydrate on an alendronic acid active basis as a unit dosage according to a continuous schedule having a dosage interval which is once weekly.
3. A method for treating or preventing osteoporosis in a human, said method comprising orally administering to said human a pharmaceutically effective amount of a pharmaceutically acceptable salt of alendronate, said pharmaceutically acceptable salt being selected from the group consisting of sodium, potassium, calcium, magnesium and ammonium salts, as a unit dosage according to a continuous schedule having a dosage interval which is once weekly.
4. A method for treating or preventing osteoporosis in a human, comprising orally administering to said human a pharmaceutically effective amount of risedronate, pharmaceutically acceptable salts or esters thereof and mixtures thereof, as a unit dosage according to a continuous schedule having a dosage interval which is once weekly.
5. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 35mg on an alendronic acid active basis of a ~~biphosphonate~~ bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof wherein said pharmaceutical composition is adapted for oral administration as a unit dosage according to a continuous schedule having a periodicity of about once-weekly.

6. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 35mg on an alendronic acid active basis of a ~~biphosphonate~~ bisphosphonate selected from the group consisting of alendronate, alendronate monosodium trihydrate or esters thereof, and mixtures thereof wherein said pharmaceutical composition is adapted for oral administration as a unit dosage according to a continuous schedule having a periodicity of about once-weekly.
7. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 35mg on an acid active basis of a ~~biphosphonate~~ bisphosphonate selected from the group consisting of risedronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof wherein said pharmaceutical composition is adapted for oral administration as a unit dosage according to a continuous schedule having a periodicity of about once-weekly.
8. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 35mg on an acid active basis of a ~~biphosphonate~~ bisphosphonate selected from the group consisting of risedronate, risedronate monosodium hemipentahydrate, or esters thereof, and mixtures thereof wherein said pharmaceutical composition is adapted for oral administration as a unit dosage according to a continuous schedule having a periodicity of about once-weekly.
9. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 70mg, on an alendronic acid basis of a ~~biphosphonate~~ bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts or esters thereof and mixtures thereof.
10. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 70mg, on an alendronic acid basis of a ~~biphosphonate~~ bisphosphonate selected from the group consisting of alendronate, alendronate monosodium trihydrate or esters thereof and mixtures thereof.

ANNEXURE 2

developed in an attempt to minimize the decline in bone mineralization while still providing a therapeutic anti-resorptive effect. Generally, cyclic regimens are characterized as being intermittent, as opposed to continuous treatment regimens, and have both treatment periods during which the bisphosphonate is administered and nontreatment periods to permit the systemic level of the bisphosphonate to return to baseline. However, the cyclic regimens, relative to continuous dosing, appear to result in a decreased therapeutic antiresorptive efficacy. Data on risedronate suggests that cyclic dosing is actually less effective than continuous daily dosing for maximizing antiresorptive bone effects. See L. Mortensen, et al., *Prevention Of Early Postmenopausal Bone Loss By Risedronate*, *Journal of Bone and Mineral Research*, vol. 10, supp. 1, p. s140 (1995), which is incorporated by reference herein in its entirety. Furthermore, these cyclic regimens do not eliminate or minimize adverse gastrointestinal effects, because such regimens typically utilize periods of multiple daily dosing. Also, the cyclic regimens are cumbersome to administer and have the disadvantage of low patient compliance, and consequently compromised therapeutic efficacy.

It is seen from current teachings that both daily and cyclic treatment regimens have shortcomings, and that there is a need for development of a dosing regimen to overcome these shortcomings.

In the present invention, it is found that the adverse gastrointestinal effects that can be associated with daily or cyclic dosing regimens can be minimized by administering the bisphosphonate at a relatively high unit dosage according to a

production has been greatly diminished. However, osteoporosis can also be steroid- induced and has been observed in males due to age. Osteoporosis can be induced by disease, e.g. rheumatoid arthritis, it can be induced by secondary causes, e.g., glucocorticoid therapy, or it can come about with no identifiable cause, i.e. idiopathic

osteoporosis. In the present invention, preferred methods include the treatment or prevention of abnormal bone resorption in osteoporotic humans.


Localized bone loss has been associated with periodontal disease, with bone fractures, and with periprosthetic osteolysis (in other words where bone resorption has occurred in proximity to a prosthetic implant).

Generalized or localized bone loss can occur from disuse, which is often a problem for those confined to a bed or a wheelchair, or for those who have an immobilized limb set in a cast or in traction.

The methods and compositions of the present invention are useful for treating and or preventing the following conditions or disease states: osteoporosis, which can include post-menopausal osteoporosis, steroid-induced osteoporosis, male osteoporosis, disease-induced osteoporosis, idiopathic osteoporosis; Paget's disease; abnormally increased bone turnover; periodontal disease; localized bone loss associated with periprosthetic osteolysis; and bone fractures.

Bisphosphonates

The methods and compositions of the present invention comprise a bisphosphonate. The bisphosphonates of the: present invention correspond to the chemical formula



The claims defining the invention are as follows:

1. A method of preventing osteoporosis in a human, comprising orally administering to said human a pharmaceutically effective amount comprising about 35 mg of alendronate monosodium trihydrate on an alendronic acid active basis as a unit dosage according to a continuous schedule having a dosage interval which is once weekly.
2. A method of treating osteoporosis in a human, comprising orally administering to said human a pharmaceutically effective amount comprising about 70mg of alendronate monosodium trihydrate on an alendronic acid active basis as a unit dosage according to a continuous schedule having a dosage interval which is once weekly.
3. A method for treating or preventing osteoporosis in a human, said method comprising orally administering to said human a pharmaceutically effective amount of a pharmaceutically acceptable salt of alendronate, said pharmaceutically acceptable salt being selected from the group consisting of sodium, potassium, calcium, magnesium and ammonium salts, as a unit dosage according to a continuous schedule having a dosage interval which is once weekly.
4. A method for treating or preventing osteoporosis in a human, comprising orally administering to said human a pharmaceutically effective amount of risedronate, pharmaceutically acceptable salts or esters thereof and mixtures thereof, as a unit dosage according to a continuous schedule having a dosage interval which is once weekly.
5. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 35mg on an alendronic acid active basis of a bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof wherein said pharmaceutical composition is adapted for oral administration as a unit dosage according to a continuous schedule having a periodicity of about once-weekly.

6. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 35mg on an alendronic acid active basis of a bisphosphonate selected from the group consisting of alendronate, alendronate monosodium trihydrate or esters thereof, and mixtures thereof wherein said pharmaceutical composition is adapted for oral administration as a unit dosage according to a continuous schedule having a periodicity of about once-weekly.
7. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 35mg on an acid active basis of a bisphosphonate selected from the group consisting of risedronate, pharmaceutically acceptable salts or esters thereof, and mixtures thereof wherein said pharmaceutical composition is adapted for oral administration as a unit dosage according to a continuous schedule having a periodicity of about once-weekly.
8. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 35mg on an acid active basis of a bisphosphonate selected from the group consisting of risedronate, risedronate monosodium hemi-pentahydrate, or esters thereof, and mixtures thereof wherein said pharmaceutical composition is adapted for oral administration as a unit dosage according to a continuous schedule having a periodicity of about once-weekly.
9. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 70mg, on an alendronic acid basis of a bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts or esters thereof and mixtures thereof.
10. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier in association with about 70mg, on an alendronic acid basis of a bisphosphonate selected from the group consisting of alendronate, alendronate monosodium trihydrate or esters thereof and mixtures thereof.